TianTan vaccinia virus-based EBV vaccines targeting both latent and lytic antigens elicits potent immunity against lethal EBV challenge in humanized mice
Xinyu Zhang,Yanhong Chen,Shuhui Wang,Ling Zhong,Zheng Xiang,Xiao Zhang,Shanshan Zhang,Xiang Zhou,Wanlin Zhang,Yan Zhou,Qiuting Zhang,Jingtong Liang,Yanran Luo,Yufei Wang,Ling Chen,Xiaoping Ye,Qisheng Feng,Mu-Sheng Zeng,Ying Liu,Yi-Xin Zeng,Yiming Shao,Miao Xu
DOI: https://doi.org/10.1080/22221751.2024.2412640
2024-10-15
Emerging Microbes & Infections
Abstract:Epstein–Barr virus (EBV) infection has been related to multiple epithelial cancers and lymphomas. Current efforts in developing a prophylactic EBV vaccine have focused on inducing neutralizing antibodies. However, given the lifelong and persistent nature of EBV infection following primary infection, it is rationalized that an ideal vaccine should elicit both humoral and cellular immune responses targeting multiple stages of the EBV lifecycle. This study used a DNA vector and a TianTan vaccinia virus to express key EBV antigens, including BZLF1, EBNA1, EBNA3B, and gH/gL, to generate multi-antigen vaccines. The multi-antigen vaccine expressing all four antigens and the multi-antigen vaccine expressing BZLF1, EBNA1, and EBNA3B showed comparable protection effects and prevented 100% and 80% of humanized mice, respectively, from EBV-induced fatal B cell lymphoma by activating BZLF1, EBNA1, and EBNA3B specific T cell. The vaccine expressing lytic protein BZLF1 elicited stronger T cell responses and conferred superior protection compared to vaccines targeting single latent EBNA1 or EBNA3B. The vaccine solely expressing gH/gL exhibited no T cell protective effects in our humanized mice model. Our study implicates the potential of EBV vaccines that induce potent cellular responses targeting both latent and lytic phases of the EBV life cycle in the prevention of EBV-induced B cell lymphoma.
immunology,infectious diseases,microbiology